



0386
#4
Gf 1632

Docket No.: 55591 (71699)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Rade, J. et al

EXAMINER: unassigned

SERIAL NO.: 09/863,803

GROUP: unassigned


FILED: May 22, 2001

FOR: GENETIC ENGINEERING OF VASCULAR GRAFTS
TO RESIST DISEASE

THE ASSISTANT COMMISSIONER OF PATENTS
WASHINGTON, DC 20231

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to The Assistant Commissioner for Patents, Washington, D.C. 20231 on July 23, 2001.

By: 
Robert L. Buchanan

Sir:


LETTER

The attached information disclosure statement (IDS) includes references that may have been available to the public less than one year or after the priority date of the above-referenced patent application. Such submission is not to be construed as an admission that the references are prior art.

It is believed that consideration of such references by the USPTO will assist understanding of the invention.

Respectfully submitted,

Date: July 23, 2001



Robert L. Buchanan (Reg. No. 40,927)
Edwards & Angell, LLP
101 Federal Street
Boston, Massachusetts 02110-1800
(617-439-4444)

#129324

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
55591

In Re Application Of: J. R. DADE, et al.

Serial No. JUL 30 2001
09/863,803 Filing Date
May 22, 2001

Examiner
not yet assigned

Group Art Unit
not yet assigned

Title: GENETIC ENGINEERING OF VASCULAR GRAFTS TO RESIST DISEASE

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 04-1105 as described below. A duplicate copy of this sheet is enclosed.
- Charge the amount of _____
- Credit any overpayment.
- Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____) on _____
(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on July 25, 2001 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Laura M. McGuire

Typed or Printed Name of Person Mailing Correspondence

*This certificate may only be used if paying by deposit account.

Signature

Robert L. Buchanan (Reg. No. 40,927)
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209

Dated: July 23, 2001

CC:

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
55591

In Re Application Of *J. P. LADE, et al.*

Serial No. **JUL 30 2001** Filing Date
09/863,803 **May 22, 2001**

Examiner
not yet assigned

Group Art Unit
not yet assigned

Title: **GENETIC ENGINEERING OF VASCULAR GRAFTS TO RESIST DISEASE**

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
 2. a Notice of Allowance under 37 CFR 1.311,
- whichever occurs first.

Also submitted herewith is:

- a certification as specified in 37 CFR 1.97(e);

OR

- the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).